These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 3657717)

  • 41. [Ergometry as a method of evaluation of antianginal drugs].
    Piña López-Yllana C
    Arch Farmacol Toxicol; 1979 Dec; 5(3):231-4. PubMed ID: 546345
    [No Abstract]   [Full Text] [Related]  

  • 42. [A new antianginal drug, bepridil: efficacy estimation by exertion test during a double blind test against a placebo (author's transl)].
    Canicave JC; Deu J; Jacq J; Paillet R
    Therapie; 1980; 35(5):607-12. PubMed ID: 6970998
    [No Abstract]   [Full Text] [Related]  

  • 43. [Changes in intracardiac hemodynamics and the tolerance for physical loading as affected by Nitrong in persons suffering from ischemic heart disease].
    Gasilin VS; Shevchenko OP; Maksumov EIu; Lupanov VP
    Biull Vsesoiuznogo Kardiol Nauchn Tsentra AMN SSSR; 1981; 4(1):59-64. PubMed ID: 6789850
    [No Abstract]   [Full Text] [Related]  

  • 44. Antianginal drugs for stable angina pectoris.
    Aronow WS
    Ration Drug Ther; 1982 Jan; 16(1):1-7. PubMed ID: 6799985
    [No Abstract]   [Full Text] [Related]  

  • 45. [Effect duration and dose-response relation of molsidomine in patients with coronary heart disease].
    Fach WA; Becker HJ
    Z Kardiol; 1984 Oct; 73(10):613-22. PubMed ID: 6393621
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Effects of strophanthin on cardiovascular function and on tolerance of exercise in patients with angina pectoris treated with beta-adrenergic blocking].
    Volta G; Pavarani A; Barbaresi F; Starcich R
    G Clin Med; 1967 Oct; 48(10):1043-53. PubMed ID: 5605712
    [No Abstract]   [Full Text] [Related]  

  • 47. [Silent myocardial ischemia].
    Specchia G; Falcone C; Rondanelli R; De Servi S; Opasich C; Ardissino D; Codega S; Corsico G; La Rovere MT; Tramarin R
    Cardiologia; 1986 Nov; 31(11):859-64. PubMed ID: 3829060
    [No Abstract]   [Full Text] [Related]  

  • 48. Extent of myocardial ischemia during coronary occlusion in single vessel disease. A comparison between patients with exercise-induced angina and patients with recurrent angina at rest.
    Figueras J; Missorici M; Gil CP; Cortadellas J; Angel J
    Int J Cardiol; 2008 Jul; 127(3):433-5. PubMed ID: 17761314
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Conservative treatment concepts for stable angina pectoris in coronary heart disease].
    Schoebel FC; Leschke M; Heintzen MP; Strauer BE
    Med Klin (Munich); 1996 Jul; 91(7):458-65. PubMed ID: 8756115
    [No Abstract]   [Full Text] [Related]  

  • 50. [Effect of sensit on the course of ischemic heart disease].
    Nesvetov VN; Gorshkov VA; Kuliamin VI; Buskin VD
    Sov Med; 1988; (3):57-61. PubMed ID: 3413552
    [No Abstract]   [Full Text] [Related]  

  • 51. Reproduction of maximal exercise performance in patients with angina pectoris despite ouabain treatment.
    Niederberger M; Bruce RA; Frederick R; Kusumi F; Marriott A
    Circulation; 1974 Feb; 49(2):309-15. PubMed ID: 4810561
    [No Abstract]   [Full Text] [Related]  

  • 52. [The evaluation of the efficacy of obzidan and sydnopharm in patients with stenocardia of effort].
    Bichko MV; Korabel'shchikova NI; Rishko NV; Rudakova SA; Dobosh VV; Kosta AM; Maksimov SD; Kashshaĭ AA
    Lik Sprava; 1992; (11-12):83-6. PubMed ID: 1292233
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Preload or afterload reduction: which is more beneficial for patients with ischemic heart disease?
    Caralis DG; Kyriakides Z
    Cardiovasc Drugs Ther; 1988 May; 2(1):79-82. PubMed ID: 3154698
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Clinical use of prostacyclin and its analogs in coronary vasculopathy].
    Lenzi S; Bugiardini R
    Ann Ital Med Int; 1986 Jun; 1(2):141-51. PubMed ID: 2484319
    [No Abstract]   [Full Text] [Related]  

  • 55. [Current data concerning the comparative effectiveness of medical and surgical treatment of coronary insufficiency. General review].
    De Vernejoul F
    Coeur Med Interne; 1979; 18(2):315-21. PubMed ID: 385218
    [No Abstract]   [Full Text] [Related]  

  • 56. [Inhibition of thrombocyte function in coronary heart disease. Results with molsidomine (Corvaton)].
    Z Kardiol; 1991; 80 Suppl 5():1-70. PubMed ID: 1776328
    [No Abstract]   [Full Text] [Related]  

  • 57. [Molsidomine in the treatment of coronary insufficiency].
    Weber S
    Rev Med Interne; 1987; 8(4):437-43. PubMed ID: 2892240
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Evaluation of the clinical usefulness of molsidomine in ischemic heart disease].
    Janicki K; Ochmański W; Kmieć M
    Pol Tyg Lek; 1986 Jun 23-30; 41(25-26):829-34. PubMed ID: 3534821
    [No Abstract]   [Full Text] [Related]  

  • 59. [Mechanisms of coronary pain and painless myocardial ischemia].
    Kuch J
    Wiad Lek; 1987 Aug; 40(15):1038-42. PubMed ID: 3324493
    [No Abstract]   [Full Text] [Related]  

  • 60. [Molsidomine in the treatment of ischemic heart disease].
    Sterkowicz S
    Wiad Lek; 1987 Oct; 40(20):1389-95. PubMed ID: 3328427
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.